• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Jefferies initiated coverage on Stoke Therapeutics with a new price target

    1/31/22 7:45:27 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STOK alert in real time by email
    Jefferies initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $50.00
    Get the next $STOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STOK

    DatePrice TargetRatingAnalyst
    12/20/2024$24.00Buy
    Chardan Capital Markets
    10/14/2024$18.00Outperform
    Leerink Partners
    3/26/2024Market Perform → Outperform
    TD Cowen
    11/20/2023Neutral
    JP Morgan
    7/25/2023Outperform → Market Perform
    TD Cowen
    5/1/2023$9.00 → $12.00Underperform → Neutral
    BofA Securities
    4/26/2023$24.00Buy
    Canaccord Genuity
    1/6/2023$22.00 → $9.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $STOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:45 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke The

      4/1/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to fund operations to mid-2028 – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syn

      3/18/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Announces CEO Transition

      Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Offi

      3/18/25 6:58:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    SEC Filings

    See more
    • SEC Form 144 filed by Stoke Therapeutics Inc.

      144 - Stoke Therapeutics, Inc. (0001623526) (Subject)

      5/1/25 4:45:41 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Stoke Therapeutics Inc.

      DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:06:17 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Stoke Therapeutics Inc.

      DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)

      4/22/25 4:05:27 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:58 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Stoke Therapeutics Inc.

      SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 4:24:49 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

      SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

      11/14/24 9:00:12 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

      – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

      9/4/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

      – Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou

      4/17/24 8:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics Appoints Ian Smith to its Board of Directors

      – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div

      9/20/23 4:30:00 PM ET
      $FHTX
      $SLDB
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $STOK
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

      – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR – – One-year study of zorevunersen will evaluate reductions in major motor seizure frequency as well as improvements in behavior and cognition in children and adolescents ages 2 to <18 years old – – FDA Breakthrough Therapy designation positions zorevunersen on efficient development path; Company plans to start Phase 3 in mid-2025 – – Webcast and conference call for analysts and investors at 8:00AM Eastern Time today – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein

      1/7/25 7:00:00 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

      Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join th

      1/6/25 4:30:00 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Ticho Barry sold $266,953 worth of shares (26,631 units at $10.02), decreasing direct ownership by 44% to 33,998 units (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      5/5/25 4:08:50 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levin Arthur A converted options into 1,210 shares (SEC Form 4)

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      4/2/25 4:03:15 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Interim CEO Smith Ian F

      4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

      3/20/25 6:19:44 PM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $STOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Stoke Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00

      12/20/24 7:51:37 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Stoke Therapeutics with a new price target

      Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00

      10/14/24 7:42:47 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stoke Therapeutics upgraded by TD Cowen

      TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform

      3/26/24 8:09:24 AM ET
      $STOK
      Biotechnology: Pharmaceutical Preparations
      Health Care